Malignant pleural mesothelioma;Les mesotheliomes malins de la plevre

Bulletin du Cancer

Volumn 86, Issue SUPPL. 3, 1999, Pages 43-54

  Gross Goupil, Maríne ^a   Ruffié, Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Mesothelioma; Pleura

Indexed keywords

5,6 DIHYDROAZACITIDINE; ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; GAMMA INTERFERON; MITOMYCIN C;

CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; GENE THERAPY; HISTOPATHOLOGY; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PROGNOSIS; REVIEW; THORAX RADIOGRAPHY; TREATMENT PLANNING; MESOTHELIOMA; PLEURA TUMOR; RISK FACTOR;

HUMANS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 0032751496     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Wagner JC. The discovery of the association of mesothelioma and asbestose exposure. Eur Respir Rev 1993; 11: 9-11.
2. Baas P, Shouwink H, Zoetmulder FAN. Malignant pleural mesothelioma. Ann Oncol 1998; 9: 139-49.
3. Inserm. Expertise collective Inserm. Effets sur la santé des principaux types d'exposition à l'amiante, I. Rapport de synthèse, Éditions Inserm, Paris, 1996.
4. Carbone M, Pass HI, Rizzo P, Marinetti M, Di Muzio M, et al. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 1997; 15: 1877-88.
5. Carbone M, Pass HI, Rizzo P, Marinetti M, Di Muzio M, Mew DJ, et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994; 9: 1781-90.
6. Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni JF, Goedert JJ, et al. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 1998; 279: 292-5.
7. Cavazza A, Travis LB, Travis WD, Wolfe JT, Foo ML, Gillespie DJ, et al. Post-irradiation malignant mesothelioma. Cancer 1996; 77: 1379-85.
8. Pappo AS, Santana VM, Furman WL, Kun LE, Walter AW, Jenkitis JJ, et al. Post-irradiation malignant mesothelioma. Cancer 1997; 79: 192-3.
9. Neugut AT, Ahsan H, Antaman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer 1997; 80: 948-50.
10. Simonato L, Baris R, Saracci R Skidmore J, Winkelmann R. Relation of environmental exposer to erionite fibres to risque of respiratory cancer. In: Bignon J, Peto J, Saracci R, eds. Non occupational exposure to mineral fibres. Lyon: ARC Scientific publications 1989; 90: 398-405.
11. Wagner JC, Skidmore JW, Hill RT, Griffiths DM. Erionite exposure and mesothelioma in rats. Br J Cancer 1985; 51: 727-30.
12. Dawson A, Gibbs A, Browne K, Pooley F, Griffiths M. Familial mesothelioma: details of 17 cases with histopathologic findings and mineral analysis. Cancer 1992; 70; 1183-7.
13. Lynch HT, Auton-Culver H, Kurosaki T. Is there a genetic predisposition to malignant mcsothclioma? In: Jaurant MC, Bignon J, eds. The mesothelial cell and mesothelioma: lung biology in health and disease series. New York: Marcel Decker 1994: 47-69.
14. Anderson M, Wallin H, Jonsson M, Nielsen LL, Visfeldt J, Vyberg M, et al. Lung carcinoma and malignant mesothelioma in patients exposed to thorotrast: incidence, histology and p53 status. Int J Cancer 1995; 63: 330-6.
15. Hillerdal G. Malignant mesothelioma 1982: review of 4,710 publicashed cases. Br J Dis Chest 1983; 77: 221-343.
16. Hughes JM, Weill H. Asbestose exposure: quantitative assessment of risk. Am Rev Resp Dis 1986; 133: 5-13.
17. Kane AB. Mechanisms of mineral fibre carcinogenesis. IARC Sci Publ 1996; 140: 11-34
18. Chailleux E, Pioche D, Chopra S, Dabouis G, Germand P, De Ljartre AY, et al. Épidémiologie du mésothéliome malin dans la région de Nantes-Saint-Nazaire: évolution 1956-1992. Rev Mal Resp 1995; 12: 353-7.
19. Roboz J, Chahinian AP, Holland JF, Silides D, Szrajer L. Early diagnosis and monitoring of transplanted human malignant mesothelioma by serum hyaluronic acid. J Natl Cancer Inst 1989; 81: 924-8.
20. Herndon JE, Green MR, Chahinian AP, Corson JM, Yasunosuke S, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-31.
21. Loddenkemper R. Thoracoscopy-state of the art. Eur Respir J 1998; 11: 213-21.
22. Ruffié P, Lehmann M, Galateau-Sallé F, Lagrange JL, Pairon JC. Standards, Options et Recommandations pour la prise en charge des patients atteints de mésothéliome malin de la plèvre. Bull Cancer 1998; 85: 545-61.
23. Galatcau-Sallé F. Immunohisrochimie des mésothéhomes: techniques et apport diagnostique actuel des marqueurs immunohistochimiques. Arch Anat Cytol Pathol 1993; 41: 212-22.
24. Probst G, Buelzebruck H, Bauer HG, Branscheid D, Vogt-Moykopf I. The role of pleuropneumonectomy in the treatment of diffuse malignant mesothelioma of the pleura. In: Deslauriers J, Lacquet LK, eds. Surgical management of pleural diseases. Vol. 6 C.V. Saint Louis: Mosby 1990; 344-50.
25. Ruffié P, Feld R, Minkin S, Cormier Y, Boutan Laroze A, Ginsberg R, et al. Diffuse malignam mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157-68.
26. Patz EF, Shaffer K, Piwnica-Worms DR, Jochelson M, Sarin M, Sugarbaker DJ, et al. Malignant pleural mesothelioma: value of CT and MRI imaging in predicting resectability. Am J Roentgenol 1992; 159: 961-6.
27. Lorigan JG, Libshitz HI. MR imaging of malignant pleural mesothelioma. J Comput Assist Tomogr 1989; 13: 617-20.
28. Rush VW. A proposed international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-8.
29. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998; 16: 145-52.
30. Boutin C, Schlesser M, Frenay C, Germain S. Mésothéliome malin: diagnostic et traitement. Rev Prat 1997; 47: 1333-9.
31. Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Menizer SJ, Lee TH, et al. Node status has prognostic significance in the multimodality therapy of diffuse malignant mesothelioma. J Clin Oncol 1993; 11: 1172-8.
32. Alberts AS, Falkson G, Goedhals L, Vorobiof D, Van der Merwe C. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527-35.
33. Butchart EG, Aschcroft R, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976; 31: 15-24.
34. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: a Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102: 1-9.
35. Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH, Healy-Baldini E, DeCamp MM, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996; 224: 288-94
36. Iaw MR, Gregor A, Hodson ME, Bloom HJ, Turner Warwick M, et al. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 1984; 39: 255-9.
37. DaValle MJ, Faber LP, Kittle CF, Jensik RJ. Extrapleural pneumonectomy for diffuse malignant mesothclioma. Ann Thorac Surg 1986; 42: 612-8.
38. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995; 108: 754-8.
39. Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB. Effect of hemirhorax irradiation alone or combined with doxorubicine and cyclophosphamide in 47 pleural mesothelioma: a nonrandomized phase II study. Eur Resp J 1996; 9: 2565-72.
40. Ong S, Vogelzang N, Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996; 14: 1007-17.
41. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998; 113: 66S-73S.
42. Planting AST, Schellens JH, Goey SH, Van der Burg ME, de Boer-Dennert M, Stoter G, et al. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 1994; 5: 373-4.
43. Solheim O, Saeter G, Finnanger A, Stenwig A. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phased II study. Br J Cancer 1992; 65: 956-60.
44. Vogelzang NJ, Herndon JE, Cirricione C, Harmon DC, Antman KH, Corson JM, et al. Dihydro-5-azacytidine in malignant mesothelioma. Cancer 1997; 79: 2237-42.
45. Sahmoud T, Postmus PE, van Pottelsberghe C, Mattson K, Tammilehto L, Splinter TA, et al. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997; 33: 2211-5.
46. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982; 96: 746-55.
47. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the cancer and leukemia group B. J Clin Oncol 1993; 11: 1559-65.
48. Samuels BL, Herndon JE, Harmon DC, Carey R, Aisner J, Corson JM, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 1998; 82: 1578-84.
49. Middleton GW, Smith IE, O'Brien MER, Norton A, Hickish T, Priest K, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatine) chemotherapy in malignant mesothelioma. Ann Oncol 1998; 9: 269-73.
50. Boutin C, Nussbaum E, Monnet I, Bignon J, Van der Schueren R, Guerin JC, et al. Inttapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74: 2460-7.
51. Astoul P, Viallat JR, van Zandwijk N, Douillard JT, Paillard JC, Guerin JC, et al. Activity of itrapleural gamma interferon in malignant mesothelioma. Cancer 1991; 67: 2033-7.
52. Eggermont AMM, Sugarbaker PH. Efficacy of chemoimmunotherapy with cyclophosphamide, interleukine 2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Camer 1988; 58: 410-4.
53. Astoul P, Viallat JR, Laurent JC, Bandely M, Boutin C. Intrapleural recombinant inrerleukine 2 in passive immunotherapy for malignant pleural effusion. Chest 1993; 103: 209-13.
54. Goey SH, Eggermom AMM, Punt CJA, Slingerland R, Gratama JW, Oosterom R, et al. Intrapleural administration of interleukine 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995; 72: 1283-8.
55. Herscher LL, Hahn SM, Kroog G, Pass H, Temeck B, Goldspiel B, Cook J et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 1998; 16: 635-41.
56. Soulić P, Ruffié P, Trandafir L, Monnet I, Tardivan A, Tenier P, et al. Combined systemic chemo-immunotherapy in advanced diffuse malignant mesothelioma: report of a phase I-II study of weekly cisplatin/interferon alpha 2a. J Clin Oncol 1996; 14: 878-85.
57. Trandafir L, Ruffié P, Borel C, Monnet I, Sotllié P, Adams D, et al. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatine-interferon combination in advanced malignant mesothelioma. Eur J Cancer 1997; 33: 1900-2.
58. Tansan S, Emri S, Selcuk T, Koc Y, Hesketh P, Herren T, et al. Teatment of malignant pleural mesothelioma with cisplatine, mitomycine C and alpha interferon. Oncology 1994; 51: 348-51.
59. Marzo AL, Fitzpatrick HR, Robinson BWS, Scott B. Antisense oligonucleotides specific for transforming growth factor beta 2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997; 57: 3200-7.
60. Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, et al. Interleukine 6 and its relationship to clinical parameters in patient with malignant pleural mesothelioma. Br J Cancer 1998; 77: 907-12.
61. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Resp Cell Mol Biol 1995; 13: 7-16.
62. Pass IH, Donington JS. Use of photodynamic therapy for the management of pleural malignancies. Sem Surg Oncol 1995; 11: 360-7.
63. Takita H, Dougherry TJ. Intracavitary photodynamic therapy for malignant pleural mesothelioma. Sem Surg Oncol 1995; 11: 368-71.
64. Antman KH, Schiff PB, Pass HI, et al. Benign and malignant mesothelioma. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. 1997; 1853-8.
65. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2. Prognosis and staging. Cancer 1993; 72: 394-404.
66. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, et al. Malignant mesothelioma of the pleura: a prospective therapeutic study of 132 patients from 1981-1985. Klin Wochenschr 1988; 66: 607-13.
67. De Pangher Manzini V, Brollo A, Franceschi S, De Matthacis M, Talamini R, et al. Prognostic factors malignant mesothelioma of the pleura. Cancer 1993; 72: 410-7.
68. Fusco V, Ardizzoni A, Merlo F, Cinquegrana A, Faravelli B, De Palm, et al. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. Anticancer Res 1993; 13: 683-9.
69. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988; 41: 525-30.
70. Tammilehto L, Tuorni T, Tiainen M, Rantonen J, Knuutila S, Pythonen S, et al. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients. Lung Cancer 1992; 66: 175-84.
71. Van Gelder T, Damhuis RA, Hoogsteden HC. Prognosis factors and survival in malignant pleural mesothelioma. Eur Respir J 1994; 7: 1035-8.